Date: 2016-11-21
Type of information: Company acquisition
Acquired company: Selexys Pharmaceuticals (USA - OK)
Acquiring company: Novartis (Switzerland)
Amount: up to $665 million in upfront, acquisition and milestone payments
Terms: • On November 21, 2016, Novartis announced it has acquired Selexys Pharmaceuticals, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis obtained the exclusive right to acquire Selexys and SelG1 in 2012. Terms of the deal could total up to $665 million in upfront, acquisition and milestone payments.
Details: Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD). Results from the study will be presented during the Plenary Scientific Session at the 58thAmerican Society of Hematology (ASH) Annual Meeting on December 4, 2016, in San Diego, California.
Related: Hematological diseases - Rare diseases
